View Older Stories View More Recent Stories

Feb 8, 2017 05:32PM Regeneron (REGN) and Sanofi (SNY) Confirm Stay of Permanent Injunction for Praluent (AMGN)
Feb 8, 2017 05:30PM Appeals Court Grants Stay of Permanent Injunction for Praluent® (alirocumab) During Appeals Process
Feb 1, 2017 01:00AM Regeneron and Sanofi Announce First Approval of Kevzara™ (sarilumab) for the Treatment of Moderately to Severely Active Rheumatoid Arthritis in Adult Patients by Health Canada
Jan 6, 2017 01:23AM Sanofi (SNY) & Regeneron (REGN) To Appeal US Court Ruling Regarding Amgen's (AMGN) Patent Claims Relating To Praluent Injection
Jan 5, 2017 10:48PM Sanofi and Regeneron to Appeal U.S. District Court Rulings in Ongoing Patent Litigation Regarding Praluent® (alirocumab) Injection
Jan 5, 2017 08:00PM Regeneron and Sanofi to Appeal U.S. District Court Rulings in Ongoing Patent Litigation Regarding Praluent® (alirocumab) Injection
Dec 8, 2016 06:21AM Regeneron (REGN), Sanofi (SNY) Announce EMA Acceptance of Dupixent Marketing App
Dec 8, 2016 01:00AM Regeneron and Sanofi Announce Marketing Authorization Application for Dupixent® (dupilumab) Accepted for Review by the EMA
Dec 2, 2016 01:20PM Global biopharma investment kicks off at Biotech Showcase™ 2017 in January
Nov 30, 2016 01:06AM ABLYNX ACHIEVES FIRST MILESTONE AS PART OF COLLABORATION WITH NOVO NORDISK
Nov 23, 2016 01:08AM ABLYNX ANNOUNCES RESULTS FOR THE FIRST NINE MONTHS OF 2016 AND A YEAR-TO-DATE BUSINESS UPDATE
Nov 22, 2016 07:30AM BioMed Realty Secures New Anchor Tenant For Iconic 500 Kendall Street Building
Nov 18, 2016 01:05AM FMR LLC ANNOUNCE 9.10% SHAREHOLDING IN ABLYNX
Nov 17, 2016 02:01AM Sanofi and Regeneron Announce Praluent® (alirocumab) Cardiovascular Outcomes Trial will Continue as Planned Following Interim Analysis
Nov 17, 2016 02:00AM Regeneron and Sanofi Announce Praluent® (alirocumab) Cardiovascular Outcomes Trial Will Continue as Planned Following Interim Analysis
Nov 16, 2016 08:01AM Regeneron (REGN), Sanofi (SNY) Announce Presentation of Strong Sarilumab Monotherapy Phase 3 Data vs. Humira
Nov 16, 2016 08:00AM Sanofi and Regeneron Present Results from Phase 3 MONARCH Study of Investigational Sarilumab at American College of Rheumatology Annual Meeting
Nov 16, 2016 08:00AM Regeneron and Sanofi Present Results from Phase 3 MONARCH Study of Investigational Sarilumab at American College of Rheumatology Annual Meeting
Nov 15, 2016 07:49AM Biogen (BIIB) Names Two New Executives for Bioverativ Spinoff
Nov 15, 2016 07:30AM Biogen Announces Additional Members of Management Team of Hemophilia Spin-off Company Bioverativ
Nov 11, 2016 09:02AM Regeneron (REGN), Sanofi (SNY) Present Praluent Phase 3 Data in Lowering LDL-C
Nov 11, 2016 09:00AM Regeneron and Sanofi to Present Data from Phase 3 Praluent® (alirocumab) Injection Clinical Trials at AHA Scientific Sessions 2016
Nov 10, 2016 01:21AM ABLYNX ANNOUNCES WARRANT EXERCISE
Nov 9, 2016 01:15AM ABLYNX TO PRESENT AT THE JEFFERIES LONDON HEALTHCARE CONFERENCE 2016
Oct 28, 2016 02:36PM Regeneron (REGN), Sanofi (SNY) Receive FDA Complete Response Letter for Sarilumab BLA as RA Treatment
Oct 28, 2016 02:35PM Regeneron and Sanofi Receive Complete Response Letter from FDA for Sarilumab, an Investigational Treatment for Rheumatoid Arthritis
Oct 21, 2016 01:03AM ABLYNX ANNOUNCES WARRANT EXERCISE
Oct 20, 2016 01:05AM ABLYNX OUTLINES NEXT STEPS FOR ITS ANTI-IL-6R NANOBODY, VOBARILIZUMAB, A POTENTIAL BEST-IN-CLASS TREATMENT FOR RHEUMATOID ARTHRITIS
Oct 19, 2016 06:00PM Pfenex Inc. Announces Formation of Scientific Advisory Board
Oct 12, 2016 01:04AM ABLYNX ANNOUNCES SECOND EXTENSION OF ITS ION CHANNEL RESEARCH COLLABORATION WITH MERCK & CO., INC.
Oct 11, 2016 01:05AM FMR LLC ANNOUNCE 9.22% SHAREHOLDING IN ABLYNX
Oct 10, 2016 01:15AM ABLYNX INITIATES A PHASE III FOLLOW-UP STUDY OF ITS FIRST-IN-CLASS WHOLLY-OWNED ANTI-vWF NANOBODY, CAPLACIZUMAB, FOR THE TREATMENT OF ACQUIRED TTP
Oct 5, 2016 08:30AM New Survey Reveals the Widespread and Serious Impact of Moderate-to-Severe Atopic Dermatitis on People Living with the Disease
Oct 5, 2016 08:30AM New Survey Reveals the Widespread and Serious Impact of Moderate-to-Severe Atopic Dermatitis on People Living with the Disease
Oct 3, 2016 06:32AM Regeneron (REGN), Sanofi (SNY) Announce Publication of Positive Dupixent Phase 3 Data as AD Treatment
Oct 1, 2016 02:00AM Regeneron and Sanofi Announce Positive Dupixent® (dupilumab) Phase 3 Atopic Dermatitis Data Published in the New England Journal of Medicine
Sep 29, 2016 01:05AM ABLYNX'S FIRST-IN-CLASS WHOLLY-OWNED ANTI-vWF NANOBODY, CAPLACIZUMAB, MAY HAVE THE POTENTIAL TO REDUCE MORBIDITY AND MORTALITY ASSOCIATED WITH ACQUIRED TTP
Sep 26, 2016 06:18AM Regeneron (REGN), Sanofi (SNY) Announce Dupilumab BLA Accepted for Priority Review by FDA
Sep 26, 2016 06:02AM Exelixis Elects Julie Anne Smith to Its Board of Directors
Sep 26, 2016 01:00AM Regeneron and Sanofi Announce Dupilumab Biologics License Application Accepted for Priority Review by U.S. FDA
Sep 15, 2016 01:07AM ABLYNX RECEIVES TRANSPARENCY NOTIFICATION FROM OPPENHEIMER FUNDS, INC.
Aug 29, 2016 07:12AM Regeneron (REGN), Sanofi (SNY) Announce Significant Results from Praluent Phase 3 in HeFH Patients
Aug 29, 2016 02:00AM Regeneron and Sanofi Present Positive Phase 3 Investigational Data for Praluent® (alirocumab) Injection in Patients Undergoing LDL Apheresis Therapy at ESC Congress 2016
Aug 29, 2016 02:00AM Regeneron and Sanofi Present Positive Phase 3 Investigational Data for Praluent® (alirocumab) Injection in Patients Undergoing LDL Apheresis Therapy at ESC Congress 2016
Aug 25, 2016 01:10AM ABLYNX ANNOUNCES 2016 HALF-YEAR RESULTS AND YEAR-TO-DATE BUSINESS UPDATE
Aug 17, 2016 01:09AM ABLYNX WILL ANNOUNCE ITS 2016 HALF YEAR RESULTS WITH WEBCAST ON 25 AUGUST 2016
Aug 12, 2016 01:06AM ABLYNX RECEIVES TRANSPARENCY NOTIFICATION FROM ADRIANUS VAN HERK ANDVAN HERK INVESTMENTS B.V.
Aug 9, 2016 01:09AM ABLYNX REPORTS COMPELLING TOPLINE PHASE IIb STUDY RESULTS WITH ITS ANTI-IL-6R NANOBODY, VOBARILIZUMAB, IN RA PATIENTS, CONFIRMING ITS BEST-IN-CLASS POTENTIAL
Aug 4, 2016 01:11AM BANK OF AMERICA CORPORATION ANNOUNCE 5.24% SHAREHOLDING IN ABLYNX
Jul 20, 2016 01:08AM ABLYNX ANNOUNCES WARRANT EXERCISE
View More Recent Stories View Older Stories